Alzheimer's Dementia, Mild Cognitive Impairment, Mild Cognitive Disorder Mental and Behavioural Disorders Alzheimer's Dementia, Mild Cognitive Impairment, Mild Cognitive Disorder
Conditions
Interventions
All study participants including healthy controls undergo the following interventions.
At screening assessment participants undergo the following assessments:
1. Rapid categorisation task- 5-6 minute
Sponsors
Cognetivity Limited
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Control group: 1. Addenbrooke’s Cognitive Examination (Revised/III) score of above 84 2. Bristol Activities of Daily Living Scale score of “unimpaired” or “mildly impaired” 3. Capacity to understand the information about the study and to give consent to participate 4. Males and females aged between 65-80 years 5. Not currently on medication that may interfere with the study results 6. In good general health 7. Matched for age and education MCI group 1. A clinical diagnosis of MCI according to ICD-10 criteria, diagnosed by an Old Age Psychiatrist 2. Mini Mental State Examination (MMSE) 24 3. Males and Females aged 65-80 years 4. Capable of indicating informed consent for participation Mild-AD group 1. A clinical diagnosis of Mild-AD according to ICD-10 criteria, diagnosed by an Old Age Psychiatrist 2. Mini Mental State Examination (MMSE) 19 3. Males and Females aged 65-80 years 4. Capable of indicating informed consent for participation
Exclusion criteria
Exclusion criteria: Control group 1. Presence of significant cerebrovascular disease ie. History of CVA 2. Major medical co-morbidities e.g. Congestive Cardiac Failure, Diabetes Mellitus with renal impairment 3. Major psychiatric disorder eg. Chronic psychosis, recurrent depressive disorder, generalized anxiety disorder 4. The use of cognitive enhancing drugs e.g. cholinesterase inhibitors 5. A concurrent diagnosis of epilepsy 6. A history of alcohol misuse 7. A history of illicit drug use 8. A history of severe visual impairment, e.g. macular degeneration, diabetic retinopathy, as determined by the clinical team 9. A history of repeated head trauma MCI group 1. Patients who fulfill criteria for a diagnosis of Mild AD 2. Major medical co-morbidities e.g. Congestive Cardiac Failure, Diabetes Mellitus with renal impairment 3. Major psychiatric disorder eg. Chronic psychosis, recurrent depressive disorder, generalized anxiety disorder 4. The use of cognitive enhancing drugs e.g. cholinesterase inhibitors 5. A concurrent diagnosis of epilepsy 6. A history of alcohol misuse 7. A history of illicit drug use Mild-AD group 1. Patients who fulfill criteria for a diagnosis of Moderate AD or Other Mild Dementias 2. Major medical comorbidities e.g. Congestive Cardiac Failure, Diabetes Mellitus with renal impairment 3. Major psychiatric disorder eg. Chronic psychosis, recurrent depressive disorder, generalized anxiety disorder 4. A concurrent diagnosis of epilepsy 5. A history of alcohol misuse 6. A history of illicit drug use 7. A history of severe visual impairment, e.g. macular degeneration, diabetic retinopathy, as determined by the clinical team 8. A history of repeated head trauma 9. MMSE scores less than 19 10. Presence of Sleep Apnoea
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. BOLD responses are measured using fMRI in <12 weeks after screening (i.e. baseline) 2. Neural activity on the skull is measured using electroencephalography (EEG) in <12 weeks after the first screening (i.e. baseline) session, and this will be one week before or after the fMRI session (in random order) 3. Level of amyloid beta and cis-p-tau-a is measured from the CSF samples for MCI patients at any time, up to three months after the baseline 4. Level of cognitive performance is measured using MoCA, ACE-R, and ICA at the baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| There are no secondary outcome measures. | — |
Countries
Iran
Contacts
Public ContactSeyed;Chris Mahdi Khaligh-Razavi;Kalafatis
;
Outcome results
None listed